Back
Speaker illustration

Mrs Ana Calejo

Serca Pharmaceuticals, Oslo (Norway)

Member of:

European Society of Cardiology

Presentations

Novel first-in-class drug candidate protects from ischemia-reperfusion injury by targeting the SERCA2 complex

Event: ESC Congress 2025

Topic: Ischaemia, Infarction, Cardioprotection

Session: Innovative therapeutic strategies to combat ischaemia-reperfusion injury and cardiac dysfunction

Access
Like
Thumbnail

New therapeutic strategy targeting regulation of the SERCA2 complex protects from myocardial ischemia-reperfusion injury

Event: ESC Congress 2023

Topic: Ischaemia, Infarction, Cardioprotection

Session: Ischaemia reperfusion

Access
Like
Thumbnail

A novel drug candidate targeting the adrenergic regulation of the SERCA2 complex protect the heart from myocardial infarct injury

Event: Heart Failure 2023

Topic: Signal Transduction, Mechanotransduction

Session: ePosters in basic science 3

Access
Like
Thumbnail

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources